J Biosci (2020) 45:100 Indian Academy of Sciences DOI: 10.1007/s12038-020-00069-8



Computational search for potential COVID-19 drugs from FDA-approved drugs and small molecules of natural origin identifies several anti-virals and plant products

ABHISHEK SHARMA<, VIKAS TIWARI< and RAMANATHAN SOWDHAMINI\*

National Centre for Biological Sciences, GKVK Campus, Bengaluru 560 065, India

\*Corresponding author (Email, mini@ncbs.res.in)

<Joint first authors

MS received 4 May 2020; accepted 23 June 2020

The world is currently facing the COVID-19 pandemic, for which mild symptoms include fever and dry cough. In severe cases, it could lead to pneumonia and ultimately death in some instances. Moreover, the causative pathogen is highly contagious and there are no drugs or vaccines for it yet. The pathogen, SARS-CoV-2, is one of the human coronaviruses which was identified to infect humans first in December 2019. SARS-CoV-2 shares evolutionary relationship to other highly pathogenic viruses such as Severe Acute Respiratory Syn-drome (SARS) and Middle East respiratory syndrome (MERS). We have exploited this similarity to model a target non-structural protein, NSP1, since it is implicated in the regulation of host gene expression by the virus and hijacking of host machinery. We next interrogated the capacity to repurpose around 2300 FDA-approved drugs and more than 3,00,000 small molecules of natural origin towards drug identification through virtual screening and molecular dynamics. Interestingly, we observed simple molecules like lactose, previously known anti-virals and few secondary metabolites of plants as promising hits. These herbal plants are already practiced in Ayurveda over centuries to treat respiratory problems and inflammation. Disclaimer: we would not like to recommend uptake of these small molecules for suspect COVID patients until it is approved by competent national or international authorities.

Keywords. Anti-virals; drug design; herbal plants; repurposing drugs; SARS-CoV-2

Abbreviations: NSP1, Non-structural protein 1; SARS-CoV2, Severe acute respiratory syndrome coronavirus 2

1. Introduction

Coronavirus (CoV) belongs to the family Coronaviri-dae and the order Nidovirales (sharing with Ar-teriviridae and Roniviridae). Coronaviruses are enveloped, long positive-sense single-stranded RNA

This article is part of the Topical Collection: COVID-19:

Disease Biology & Intervention.

viruses, which are best known for causing mild to severe respiratory and enteric infection among a vast range of hosts (Masters [2006](#page17)). These are further divi-ded into 4 groups/genera named as Alphacoronavirus (a-CoV), Betacoronavirus (b-CoV), Gammacoron-avirus (c-CoV) and Deltacoronavirus (d-CoV), based on sequence similarities and antigenic cross-reactivity. Human-CoV belongs to group I and group II of Beta-coronavirus. HCoV-OC43, HCoV-229E, SARS and MERS are some examples of Human-CoV, out of which SARS and MERS are highly pathogenic in nature (Masters [2006](#page17); Narayanan et al. [2015](#page17)). Recently, a new pathogenic Human-CoV strain known

Electronic supplementary material: The online version of this article (<https://doi.org/10.1007/s12038-020-00069-8>) contains supplementary material, which is available to authorized users.

[http://www.ias.ac.in/jbiosci](http://www.ias.ac.in//jbiosci)



100 Page 2 of 18 A Sharma, V Tiwari and R Sowdhamini

as SARS-CoV2, spreading the COVID-19 infection, has emerged by December 2019 with Wuhan of Hubei province in China as the epicenter (Wu et al. [2020a](#page17), [b](#page18)). The origin of this virus is still under investigation but has been speculated as a zoonotic shift from bat to human. It has been shown that human ACE2 has a high predicted affinity than ACE2 from other species (Pi-plani et al. [2020](#page17)). The outbreak of COVID-19 has spread across the globe and has taken the shape of a pandemic (Novel Coronavirus (2019-nCoV) situation reports, World Health Organization). America, Russia, United Kingdom, India, Italy, Spain, and France are among worst-hit countries. As of 14 June 2020, this has infected 7,891, 289 individuals and has caused more than 432,746 fatalities across the globe (Johns Hopkins Coronavirus Resource Center; Worldmeter. [https://](https://www.worldometers.info/coronavirus/) [www.worldometers.info/coronavirus/](https://www.worldometers.info/coronavirus/); Novel Coron-avirus (2019-nCoV) situation reports - World Health Organization). At present, there are no drugs or vac-cines available against this, and patients are treated according to symptoms shown by them. Remdisivir (drug originally designed to treat Ebola), Colchicine (Deftereos et al. [2020](#page16)), Chloroquine and Hydroxy-chloroquine (an antimalarial drug), Kevsara (an arthritis drug) and few other antiviral drugs are being considered for treatment. But they do not directly make use of the virome of SARS-CoV2 (Wang et al. [2020](#page17)) ([https://www.nasdaq.com/articles/8-experimental-corona](https://www.nasdaq.com/articles/8-experimental-coronavirus-treatments-to-watch-2020-03-31) [virus-treatments-to-watch-2020-03-31](https://www.nasdaq.com/articles/8-experimental-coronavirus-treatments-to-watch-2020-03-31)). Multiple vaccine trial has been going on worldwide, among which Bacillus Calmette Guerine (BCG) live attenuated vac-cine and AZD1222 are in phase 2/3 of the clinical trials. ([https://www.raps.org/news-and-articles/news-articles/](https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker) [2020/3/covid-19-vaccine-tracker](https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker))

The first genome of the COVID-19 strain was sequenced by Wu et al. ([2020b](#page18)) from a 41-year-old man and was found to be closely similar to SARS-CoV. The structural component of the virus consists of four proteins: Spike (S), Membrane (M), Envelope (E) and Nucleocapsid (N) protein respectively. S protein is critical for viral infection as it enables host-pathogen interaction and mediated viral entry into the host cell. M protein is a multipass transmembrane protein, a major constituent of virion envelope, and known to provide its shape. E protein, unlike the name, suggests it is a minor constituent of the envelope and 80–120 aa in length. N protein as the name suggests forms helical nucleocapsid of virion (Masters [2006](#page17)).

The 50 -end of the genome encodes two open reading frames, ORF1a and ORF1b, respectively, which code for all non-structural proteins (NSP1-16) (Masters [2006](#page17); Narayanan et al. [2015](#page17)). These proteins are

essential for viral replication as well as infection, whereas the function of some is yet to be identified. Among these non-structural proteins within the CoV family, some are conserved in sequence, whereas oth-ers are highly diverged in nature. NSP1 (non-structural protein 1) is one of such diverged proteins which is encoded by ORF1a and varied in amino-acid length among CoV-groups (Narayanan et al. [2015](#page17)). COVID-19 NSP1 consists of 180 and shows sequence similarity with SARS protein (Elbe and Buckland-Merrett [2017](#page16); Wu et al. [2020a](#page17)). Despite differences in amino acid sequence and length, it has shown to be functionally highly conserved (Narayanan et al. [2015](#page17); Shen et al. [2019](#page17)). SARS-CoV NSP1 is most well-studied amongst the viruses of the coronavirus family. NSP1 has shown to act as a virulence factor (Huang et al. [2011](#page16); Nar-ayanan et al. [2015](#page17); Zst et al. [2007](#page18)) and mutation in this protein results in the production of attenuated virus in vitro and in vivo (Zst et al. [2007](#page18)). NSP1 deploys two strategies to inhibit host cell expression viz. Inhibition of host translation and Induction of host mRNA degradation. It inhibits host translation by forming a complex with 40s ribosome subunit, which prevents the formation of active polysome. Complex formation with 40s subunit also shown to inhibit its translational ability (Kamitani et al. [2009](#page16)). It further affects host cell gene expression by inducing host mRNA degradation in a template-specific manner. Term template-specific does not imply its association with protein sequence but relates to the ability to specifically degrade capped host mRNA (Huang et al. [2011](#page16); Kamitani et al. [2006](#page16), [2009](#page16); Narayanan et al. [2008](#page17); Tanaka et al. [2012](#page17)) as compared to SARS-mRNA (Kamitani et al. [2006](#page16)). mRNA is hypothesized to get cleaved by unknown host endonuclease since NSP1 does not possess any endonucleolytic activity. Other than these, NSP1 is shown to cause chemokine dysregulation which cor-relates with high inflammation in severe patients (Law et al. [2007](#page16); Channappanavar and Perlman [2017](#page16); Wong et al. [2004](#page17)). It suppresses innate immune response by degrading IFN-beta mRNA (Tanaka et al. [2012](#page17)) and affecting antiviral signaling (Jauregui et al. [2013](#page16)). Yeast-two hybrid assays have shown NSP1 to interact with multiple host proteins (Pfefferle et al. [2011](#page17)). N-terminal region is shown to be important in immune response dysregulation (mutation studies) (Jauregui et al. [2013](#page16)) and protecting viral RNA (R124, present in our dock site) (Tanaka et al. [2012](#page17)). The C-terminal region is critical of transcriptional inhibition of host mRNA (Narayanan et al. [2015](#page17); Tanaka et al. [2012](#page17)).

In this study, COVID-19 NSP1 is the target protein and we hypothesized that the inhibition of NSP1 can

Computational search for potential COVID-19 drugs Page 3 of 18 100

potentially attenuate the virus and suppress adverse immune-pathology caused by it. We have generated a homology model of the NSP1 and used this model to carry out virtual screening to identify potential inhibi-tors and lead compounds. Our searches are directed within the database of FDA-approved drugs (DRUG-BANK) and those which are derived from molecules of natural origin (SUPERNATURALDB). Finally, we performed MD simulation to ensure that there are indeed stable protein-ligand interactions when the system is visualized to undergo limited conformational freedom. We find several anti-viral compounds, few secondary metabolites of plant origin and simple compounds (like lactose) to retain the high potential to act as NSP1 inhibitors.

2. Methods

2.1 Sequence retrieval and analysis

The full repository of COVID-19 protein sequences was downloaded from NCBI (Brister et al. [2015](#page16); Hatcher et al. [2017](#page16)). Wuhan-Hu-1 strain [Accession number: NC\_045512] was among the first to be sequenced from Wuhan of Hubei province. Hence this is considered as the ‘reference genome’ in this study. NSP1 protein sequences were extracted, incomplete sequences were removed and curated sequences were then passed to SNP analyzer (utility in ViPR Database) to understand variation among the NSP1 sequences (Pickett et al. [2012](#page17)). A similar analysis had been done for the Indian sequences. To understand evolutionary pressure on NSP1 protein Shannon entropy (Shannon [1948](#page17)) per residue has been calculated using a python script. A set of key residues, important in suppressing host gene expression and antiviral signaling were identified. A mutation study done by another group (Jauregui et al. [2013](#page16)) was used as a reference.

2.2 Homology modelling

NSP1 protein sequence [Accession number: YP\_009725297] was retrieved from NCBI for Homology modelling. Blastp (Camacho et al. [2009](#page16)) was used to search for the nearest structural homologue in Protein Data Bank (PDB) (Berman et al. [2003](#page16)) to serve as a template for modelling. Segments of NSP1 sequence, where the association with the template was unknown, were removed. Modeller 9.12 (Eswar et al. [2006](#page16)) was used for Homology modelling. Homology

models were first filtered according to DOPE score. Top 3 predicted models were then subjected to struc-ture validations (by using SAVES 5.0 (Laskowski et al. [1993](#page16)) (<https://servicesn.mbi.ucla.edu/SAVES/>) and ProSA server (Wiederstein and Sippl [2007](#page17))). Based on DOPE score, Ramachandran plot and ProSA profile, the best predicted model was selected for virtual screening.

2.3 Virtual screening of inhibitors

FDA-approved drugs and Super Natural II database (database of natural products) were used for docking purposes. FDA-approved drugs were downloaded in SDF format (Standard Delay Format) from Drug-bank (Wishart et al. [2018](#page17)) whereas supernatural compounds were obtained from supernatural database (Banerjee et al. [2015](#page16)).

2.3.1 Ligand and protein preparation: Downloaded compounds were prepared for screening using Ligprep module in Schrodinger (Schro¨ dinger Release 2019-4: LigPrep, Schro¨ dinger, LLC, New York, NY, 2019). For FDA-approved drugs OPLS3e force field, targeted pH 7.4 ?/-0.0, retain specified chiralities and 1 structure per ligand was specified during ligand preparation. For supernatural database we had specified pH range from 6.0 to 8.0 with maximum 32 structure per ligand. This was performed to scan and produce broad chemical and structural diversity from each molecule.

Protein was prepared for docking by using Protein-preparation wizard (Sastry et al. [2013](#page17)) in Maestro Schrodinger (Schro¨dinger Release 2019-4: Maestro, Schro¨dinger, LLC, New York, NY, 2019.)

2.3.2 Docking site prediction: SiteMap (Halgren [2007](#page16); Halgren [2009](#page16)) was used to predict the potential drug-able deep and shallow sites on the target protein. The site with high S-score, as well as D-score, was selected for ligand docking.

2.3.3 Receptor grid generation: Receptor-grid around docking region on the protein was generated using receptor-grid generation module in Glide, Residues from top predicted deep and shallow sites were speci-fied and rotatable bonds across the site (if any) were checked during grid generation.

2.3.4 Protein–ligand docking: Using the glide docking module, a library of prepared ligands and protein with prepared receptor binding grid were docked. First,

100 Page 4 of 18 A Sharma, V Tiwari and R Sowdhamini

High-throughput virtual screening (HTVS) was per-formed. This narrowed down the list of potential ligands and the top 10 percent from this were then screened with Standard Precision (SP) mode. Finally, 10 percent of hits obtained from SP were passed to Extra precision (XP). Selection of top 10 percent compounds were done based on top dock score and binding energy (Friesner et al. [2004](#page16); Friesner et al. [2006](#page16); Halgren et al. [2004](#page16)) (Schro¨ dinger Release 2019-4: Glide, Schro¨dinger, LLC, New York, NY, 2019.)

Binding energy was calculated using MM-GBSA (Molecular Mechanics energies combined with the Generalized Born and Surface Area continuum solva-tion) tool of Schrodinger.

2.4 MD simulations

The conformer of protein–ligand complex, emerging from XP docking, was assembled using system builder and subject to Molecular Dynamics using the Desmond package of Schrodinger (Bowers et al. [2006](#page16)). For water, the TIP4P model was specified and orthorhom-bic box shape was used having a buffer distance of 10 A˚. Box volume was minimized. The system was neu-tralized and 150 mM salt (NaCl) was added. The output of the system builder was used for MD. The default relaxation protocol was used to relax the solvated system followed by production MD run for 20 nanoseconds (ns). The relaxation protocol involves energy minimization steps using the steepest descent method with a maximum of 2000 steps. The energy minimization was done with solute being restrained using 50 kcal/mol/A˚ force constant on all solute atoms and without restraints. Energy minimization was fol-lowed by short MD simulation steps which involve (1) Simulation for 12 picoseconds at 10 K in NVT ensemble using Berendsen thermostat with restrained non-hydrogen solute atoms, (2) Simulation for 12 picoseconds at 10 K and 1 atmospheric pressure in NPT ensemble using Berendsen thermostat and Berendsen barostat with restrained non-hydrogen solute atoms, (3) Simulation for 24 picoseconds at 300 K and 1 atmospheric pressure in NPT ensemble using Berendsen thermostat and Berendsen barostat with restrained non-hydrogen solute atoms, (4) Simu-lation for 24 picoseconds at 300 K and 1 atmospheric pressure in NPT ensemble using Berendsen thermostat and Berendsen barostat without restraints. After relax-ation, production MD was run in NPT ensemble using OPLS 2003 force field (Harder et al. [2016](#page16)). For

simulations, default parameters of RESPA integrator (Humphreys et al. [1994](#page16)) (2 femtoseconds time step for bonded and near non-bonded interactions while 6 femtoseconds for far non-bonded interactions) were used. The temperature and pressure were kept at 300K and 1 bar using the Nose-Hoover chain method (Mar-tyna et al. [1992](#page17)) and the Martyna-Tobias-Klein method (Martyna et al. [1994](#page17)) respectively. The production MD was run for 20 nanoseconds.

2.5 Simulation analysis

MD simulation analysis was performed using the Simulation interaction diagram (SID) module of the Desmond package. The entire range of simulation time was considered for all analyses. RMSD is calculated for each frame by aligning the complex to the protein backbone of the reference frame. Significantly higher values of ‘Lig fit Prot’ than protein RMSD signifies the diffusion of ligand away from its initial binding site. Lig fit lig RMSD is calculated by aligning the ligand on the reference ligand conformation and it indicates the internal fluctuation of the ligand. Along with RMSD, the RMSF (Root Mean Square Fluctuation) was also assessed for each MD run. Protein RMSF shows the fluctuation of protein residues, highlights secondary structure (Pink: a helix; Blue: b strand) and ligand interacting residues marked by green vertical lines. Protein-ligand interactions were also monitored throughout the simulation time. Different types of protein-ligand interactions measured. are H-bond, Hydrophobic interaction, ionic interaction and water bridges. Hydrophobic interaction also includes P-Ca-tion and P-P interactions. The normalized stacked bar charts suggest the fraction of simulation time for which interaction is maintained over the course of the simu-lation trajectory: for example, a value of 0.6 implies that a specific interaction is maintained for 60% of the simulation time. If a protein residue makes multiple interactions of the same type with ligand then values more than 1.0 are possible.

2.6 ADME prediction

ADME: ‘absorption, distribution, metabolism, and excretion’ properties for selected compounds from supernatural database has been done using Qikprop tool of Schrodinger suite. A star is assigned if the value of the query compound falls beyond the 95% range of similar values for known drugs. Therefore, a greater

Computational search for potential COVID-19 drugs Page 5 of 18 100

number of stars indicates less drug-likeliness of the compound.

3. Results

3.1 Sequence Analysis identified COVID-19 NSP1 to be conserved

Around 10,000 complete NSP1 sequences of SARS-CoV2 were available in the public domain (NCBI as of 14 June 2020) and downloaded. Out of these, 6383 were sequences deposited from USA, 1829 from Australia, 446 from India and196 from Greece. Within India, 202 were sequences deposited from Ahmedabad, 40 from Vadodara and 26 from Gandhinagar. Analysis of Indian sequences between two time points, 15 May 2020 and 10 June 2020, clearly shows NSP1 to be evolving. In the dataset of 15th May, only one residue mutation (S135N) was observed. However, in the dataset corresponding to the second time point, three additional residues were found to be mutated (V38F, D147E, V167A (supplementary figure 1). Mutation analysis of the entire set of around 10,000 sequences shows mutation at multiple residues. Shannon entropy is found to be close to 0 for most of the residues (with a maximum \0.2). This indicates NSP1 is not under huge selection pressure and can be considered as highly conserved till now. In the absence of the available structure of NSP1 of SARS-CoV2, we included SARS NSP1 as a template for modeling. The major reason for this assumption is 100% query coverage and 84.44% sequence similarity of SARS-CoV2 NSP1 with SARS NSP1 (figure [1](#page5)a). We performed an extensive literature survey to identify a set of key residues, important in



suppressing host gene expression and antiviral signal-ing which are shown in figure [1](#page5)b. Most of the residues among this set are found to be conserved between COVID and SARS NSP1.

3.2 Model for virtual screening generated by homology modelling

Blastp search of COVID-19 NSP1 sequence with PDB database enabled to identify 2hsx as the best template (with 68% query coverage and 86% identity). N- and C-terminal overhangs in SARS CoV-2 NSP1 have not been considered for modelling. Amino acid variations and key residues, important for function, are marked on the alignment (figure [1](#page5)). Predicted models, derived using Modeller 9.22, were sorted according to the DOPE score and the top three models were validated using ProSA and SAVES5.0 sever. The best model from the above was chosen for virtual screening (figure [2](#page6)a).

3.3 List of potent inhibitors are identified by in silico screening of FDA-approved drugs and Supernatural Database compounds

Three deep and five shallow ligand binding sites could be recognized on the surface of COVD19-NSP1 pro-tein. Sites were ranked according to their ability to bind various ligands which were depicted as SITEMAP site score and D-Score (please see Methods). We selected Site 1 with a site score of 0.927 and D-score 0.791 among deep sites and site 3 with site score 0.883 and D-score 1.012 among shallow sites for ligand docking

Figure 1. Sequence analysis COVID-19 (Wuhan-Hu-1) Nsp1. Represents alignment between Wuhan-Hu-1 Nsp1 and SARS Nsp1 protein sequence. Red highlights consensus sequences whereas Blue highlights difference in amino-acid sequence. Important residues shown to play role in affecting host gene expression and anti-viral signaling are highlighted in green and pink color. Green highlighting similar residues whereas Pink highlighting residues which are different in COVID-19.

100 Page 6 of 18 A Sharma, V Tiwari and R Sowdhamini




Figure 2. Model of COVID-19 (Wuhan-Hu-1) Nsp1 with Deep and shallow binding site predicted by SiteMap: (a) COVID-19 Nsp1 model derived using Modeller 9.22, using 2hsx as a template. Red dot represents Shallow binding site consisting region of alpha-helix and beta-sheets. Blue dots represent deep binding site present in mostly loop region. (b) Residues present in deep and shallow binding site respectively. Residue numbers are as per the structural model (Residue 1 of structure is residue 12 in the sequence)

(figure [2](#page6)a). These sites also contain functionally important residues (figure [1](#page5)) which showed their bio-logical importance. Selected sites were then used to generate a receptor grid for molecular docking. Molecular docking for each site was carried out using a glide dock program with generated libraries of 2413 FDA-approved drugs and 3,25,287 natural compounds, respectively. The top hits from FDA-approved drug library were ranked according to their XP and MMGBSA scores. We have also considered ligands with well-known anti-viral and anti-inflammatory properties, along with top-ranked ones (entries 15–17 in table [1](#page7)). The final list of compounds was taken further for the MD simulation run (table [1](#page7)). The top hits from Supernatural Database compounds were ranked according to their MMGBSA score and were further selected for MD simulation runs. List of top hits, selected based on either binding energy or mode of action, for both deep and shallow binding sites are shown in table [1](#page7).

3.4 MD simulation of protein–ligand complexes


The best compounds from docking analysis were fur-ther subjected to 20 ns of MD simulation to assess the stability of protein–ligand complex. The interactions between protein and ligand were designated as stable if

there was less structural variations and a high per-centage of hydrogen bonds or hydrophobic interactions with various residues of the protein at the docked site throughout the course of the simulations. Among the FDA-approved drugs docked at the deep site, Esculin is an example of stable complexes, while Zinc-gluconate is an example of an unstable complex. Figure [3](#page13)a and supplementary figure 2a show the interaction of Esculin with NSP1 in the docking pose, where Esculin interacts mainly with Arg62, Ser63, Ala68 and His72. MD simulation of NSP1-deep-Esculin complex for 20 ns revealed the stability of the complex as assessed by the RMSD (root mean square deviation) plot. Residues in the secondary structure are expected to have fewer fluctuations than residues in the loop regions and the trend is followed for NSP1 which shows high RMSF between residues 62-76 which form a loop and also interact with Esculin (supplementary figure 2b). Arg62, Ser63, Ala68 and His72 (major interacting residues in the docking pose) interact mainly through H-bond interactions with Esculin. Met74 was also found to interact with Esculin mainly through H-bond (fig-ure [3](#page13)b). Few other residues interact with Esculin, but with less amount of simulation time. Further details of these interactions are provided in supplementary fig-ure 2c and d.

Results of similarly detailed analysis for all the ligands, as in table [1](#page7), are provided in Supplementary

Table 1. Top-ranking hits identified by the virtual screening and other promising small molecules

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Deep binding site |  |  |  | Shallow binding site | | |  |  |  |
| No. | Compound | Structure | Source |  |  |  |  |  |  |  |  |  | Comment |  |
|  |  |  |  |  | MMGBSA |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | XP Score | MMGBSA score | MD |  | XP Score | score | MD | |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 1 | Esculin |  | Drugbank | 2 6.883 | 2 29.24 | Stable |  |  |  |  |  | Vast-Protective agent, antioxidant | |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | and anti-inflammatory (Wishart |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | et al. 2018) |  |
| 2 | Cidofovir |  | Drugbank | 2 5.776 | 2 16.53 | Stable |  |  |  |  |  |  | Anti-viral (Wishart et al. 2018) |  |
| 3 | Mesalazine |  | Drugbank | - 5.146 | - 20.74 | Not stable |  |  |  |  |  |  | Anti-inflammatory agent (Wishart |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | et al. 2018) |  |
| 4 | Lactose |  | Drugbank | 2 11.16 | 2 40.72 | Not stable |  |  |  |  |  |  | It is a disaccharide of glucose and |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | galactose. Used as a nutrient |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | supplement (Wishart et al. 2018) |  |
| 5 | FAD |  | Drugbank | - 7.895 | - 52.47 | Not stable | - 5.643 | | - 40.25 | Not stable | | Used in ophthalmic treatment for | |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | vitamin B2 deficiency (Wishart |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | et al. 2018) |  |



6 Salmeterol Drugbank - 5.69 - 47.8 Not stable Beta-2 adrenergic receptor agonist.



Used in treatment of asthma and


COPD (Wishart et al. 2018)

|  |
| --- |
| Computational search for potential COVID-19 drugs |

|  |
| --- |
| Page 7 of 18 100 |


Table 1. (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Deep binding site |  |  |  | Shallow binding site |  |  |  |
| No. | Compound | Structure | Source |  |  |  |  |  |  |  | Comment |  |
|  |  |  |  |  | MMGBSA |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | XP Score | MMGBSA score | MD | | XP Score | score | MD | |  |
|  |  |  |  |  |  |  | |  |  |  |  |  |
| 7 | Zinc |  | Drugbank | - 8.525 | - 18.19 | Not stable | |  |  |  | Treating diarrheal episodes in |  |
|  | gluconate |  |  |  |  |  |  |  |  |  | children |  |
|  |  |  |  |  |  |  |  |  |  |  | and reduced duration of common |  |
|  |  |  |  |  |  |  |  |  |  |  | cold (Wishart et al. 2018) |  |
| 8 | Salbutamol |  | Drugbank | - 5.097 | - 40.86 | Not stable | |  |  |  | A short-acting, beta-2 adrenergic |  |
|  |  |  |  |  |  |  |  |  |  |  | receptor agonist (Wishart et al. |  |
|  |  |  |  |  |  |  |  |  |  | 2018) | |  |




|  |
| --- |
| 100 Page 8 of 18 |


|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 9 | Fenoterol | Drugbank | - 6.543 | - 45.18 | Not stable |
| 10 | Nelarabine | Drugbank | - 6.307 | - 36.86 | Not stable |




11 Ioxilan Drugbank - 8.451 - 35.28 Not stable



12 Edoxudine Drugbank 2 5.941 2 33.63 Stable



13 Floxuridine Drugbank - 5.125 - 33.27 Not stable



Adrenergic beta-2 receptor agonist

(Wishart et al. 2018)

Anti-neoplastic agent (Wishart et al.

2018)

Tri-iodinated diagnostic contrast

agent (Wishart et al. 2018)

Deoxy-thymidine analog and Anti-

viral

agent [26]

Anti-neoplastic and antimetabolite


agent

(Wishart et al. 2018)

|  |
| --- |
| A Sharma, V Tiwari and R Sowdhamini |

Table 1. (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Deep binding site | |  | Shallow binding site | | |  |  |
| No. | Compound | Structure | Source |  |  |  |  |  |  |  | Comment |  |
|  |  |  |  |  | MMGBSA |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | XP Score | MMGBSA score | MD |  | XP Score | score | MD |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| 14 | Brivudine |  | Drugbank | 2 5.8 | 2 30.61 | Stable |  |  |  |  | Anti-viral (Wishart et al. 2018) |  |
| 15 | Remdesivir |  | Drugbank | 2 5.795 | 2 40.01 | Stable |  |  |  |  | Anti-viral agent, a potential |  |
|  |  |  |  |  |  |  |  |  |  |  | treatment for Ebola and shown |  |
|  |  |  |  |  |  |  |  |  |  |  | to be effective against |  |
|  |  |  |  |  |  |  |  |  |  |  | COVID-19 (Wang et al. 2020; |  |
|  |  |  |  |  |  |  |  |  |  |  | Wishart et al. 2018) |  |
| 16 | Ritonavir |  | Drugbank | - 2.778 | - 27.75 | Not stable | - 2.25 | | - 55.25 | Not stable | Anti-viral agent (Wishart et al. |  |
|  |  |  |  |  |  |  |  |  |  |  | 2018) |  |
| 17 | Brincidofovir |  | Drugbank | - 2.024 | - 27.75 | Not stable |  |  |  |  | Anti-viral agent (Wishart et al. |  |
|  |  |  |  |  |  |  |  |  |  |  | 2018) |  |
| 18 | Galangin |  | Natural product | - 3.532 | - 17.69 | Not stable | - 2.278 | | - 22.99 | Not stable | Dietary flavonoid having anticancer |  |
|  |  |  |  |  |  |  |  |  |  |  | properties (Chen et al. 2019) |  |
| 19 | Glycyrrhizic Acid |  | Drugbank | 2 4.609 | 2 23.59 | Not stable | 2 3.643 | | 2 27.06 | Stable | Anti-inflammatory, anti-diabetic, |  |
|  |  |  |  |  |  |  |  |  |  |  | anti-oxidant, anti-tumor and |  |
|  |  |  |  |  |  |  |  |  |  |  | anti-viral properties (Ming and |  |
|  |  |  |  |  |  |  |  |  |  |  | Yin 2013) |  |
| 20 | SN00003849 |  | Super | 2 6.295 | 2 51.08 | Stable |  |  |  |  | Plant product |  |
|  |  |  | natural database |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |




|  |
| --- |
| Computational search for potential COVID-19 drugs |


|  |
| --- |
| Page 9 of 18 100 |

Table 1. (continued)


|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Deep binding site | |  | Shallow binding site | | | | |  |
| No. | Compound | Structure | Source |  |  |  |  |  |  |  |  | Comment |  |
|  |  |  |  |  | MMGBSA |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | XP Score | MMGBSA score | MD |  | XP Score | score |  | MD | |  |
|  |  |  |  |  |  |  |  | |  |  |  | |  |
| 21 | SN00220639 |  | Super | - 12.25 | - 50.79 | Not stable | - 10.59 | | - 67.94 | Not stable Plant product | | |  |
|  |  |  | natural database |  |  |  |  |  |  |  |  |  |  |




|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| 22 | SN00103215 | Super | - 5.264 | - 47.66 | Not stable | Plant product |
|  |  | natural database |  |  |  |  |




|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| 23 | SN00003832 | Super | 2 6.308 | 2 47.03 | Stable | Plant product |
|  |  | natural database |  |  |  |  |



|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 24 | SN00216190 | Super | 2 7.78 | 2 46.11 | Stable |  |  |  | Plant product |
|  |  | natural database |  |  |  |  |  |  |  |
| 25 | Acarbose | Drugbank |  |  |  | 2 8.365 | 2 28.35 | Stable | Anti-diabetic (Wishart et al. |
|  |  |  |  |  |  |  |  |  | 2018) |



|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| 26 | Omadacycline | Drugbank | - 6.025 | - 35.52 | Not stable | Antibiotic (Wishart et al. |
|  |  |  |  |  |  | 2018) |
|  |  |  |  |  |  |  |



|  |
| --- |
| 100 Page 10 of 18 |


|  |
| --- |
| A Sharma, V Tiwari and R Sowdhamini |

Table 1. (continued)


|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | Deep binding site |  |  |  | Shallow binding site | |  |  |  |
| No. | Compound | Structure | Source |  |  |  |  |  |  |  | Comment |  |
|  |  |  |  | MMGBSA |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | XP Score MMGBSA score | MD |  | XP Score | score | MD |  |  |  |
|  |  |  |  | |  |  | |  |  |  |  |  |
| 27 | Iopromide |  | Drugbank | |  | 2 4.73 | | 2 31.58 | Stable | Used as a contrast agent | |  |
|  |  |  |  |  |  |  |  |  |  |  | (Wishart et al. 2018) |  |




|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 28 SN00037405 | Super | - 9.177 | - 61.45 Not stable | Plant product |
|  | natural database |  |  |  |



|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 29 SN00161170 | Super natural | - 6.676 | - 57.94 Not stable | Plant product |
|  | database |  |  |  |




|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 30 SN00038342 | Super | - 6.066 | - 51 | Not stable | Plant product |
|  | natural database |  |  |  |  |
|  |  |  |  |  |  |



|  |
| --- |
| Computational search for potential COVID-19 drugs |

|  |
| --- |
| Page 11 of 18 100 |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 100 | | Page 12 of 18 | | | | |  |  |  |  |  |  |
|  |  | Comment |  | Anti-obesity, Anti-inflammatory | (Suk et al. [2017](#page17);andantibiotic | Rampogu et al. [2018](#page17)) | Anticancer, anti-oxidant, | antimicrobial, anti-inflammatory | anti-allergic and antibiotic | (Rampogu et al. [2018](#page17); Semwaletal.[2015](#page17)) |  |  |
|  |  |  |  |  |
|  |  | MD |  | done |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  | site | MMGBSAscore |  | Not |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  | Shallow binding |  | 2 36.38 |  |  |  |  |  |  |  |  |
|  | XP Score | 2 2.578 | |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  | MD |  | Not | done |  | Not | done |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  | Deep binding site | MMGBSA score |  | 2 22.27 |  |  | 2 36.18 |  |  |  |  |  |
|  |  | XP Score |  | 2 4.39 |  |  | 2 2.64 |  |  |  |  |  |
|  |  |  |  |  |  | database |  |  | database |  |  |  |
|  |  | Source |  | Super | natural | Super | natural |  | text. |  |
|  |  | Structure |  |  |  |  |  |  |  |  | been discussed in the |  |
| (continued)Table1. |  | No. Compound |  | 31 SN00156190 | (Gingerenone) |  | 32 SN00002189 | (Shogaol) |  |  | Molecules marked in havebold |  |



A Sharma, V Tiwari and R Sowdhamini

figures S1–S35. Other promising lead compounds, among the FDA-approved ligands docked at the deep site of NSP1, are Cidofovir (supplementary figure 3), Remdesivir (the drug under investigatory group; sup-plementary figure 17), Brivudine (supplementary fig-ure 16) and Edoxudine (supplementary figure 14). In the case of FDA-approved drugs docked at the shallow site, acarbose was found to be the most stable ligand. It interacts mainly with Arg32, Leu77 and Asn115 through H-bond and water bridge interactions (sup-plementary figure 31).

Amongst compounds from SuperNatural database docked at the deep binding site of NSP1, SN00003849 interacts mainly with Arg62, Arg66, Ala68, Gly71, His72 and Met74 (figure [4](#page13)a). Further, the NSp1-SN00003849 complex was found to be stable, as suggested by RMSD plot of 20ns MD simulation (supplementary figure 25a). Residues interacting with SN00003849 are similar to that of Esculin (supple-mentary figure 25b). These include Arg62, Arg66, Gly71, His72 and Met74 interacting mainly through H-bond and water bridge interactions (figure [4](#page13)b). Arg61, Gly71 and Met74 interact with the same atom of SN00003849 for more than 80% of simulation time (supplementary figure 25c). At any point during the simulation, the minimum number of contacts between SN00003849 and NSP1 is more than four, suggesting the strong interaction at the binding site (supplemen-tary figure 25d). SN00003849 also has the highest binding energy as per MM-GBSA calculation (table [1](#page7)). SN00003849 is structurally similar to terpene/steroid and can be classified as proto and pseudo alkaloids. SN00003832 and SN00216190 also form a stable complex with NSP1 at the deep site (supple-mentary figures 29 and 30).

For shallow binding sites, none of the compounds in supernaturaldb form complex that are as stable as that for the deep binding site. Natural compounds (entries 18, 19, 32 and 33) are derived from herbal plants, well-known to treat coughs and viral fevers. Another FDA-approved compound is Glycyrrhizic acid which was ranked a bit lower for the deep site, as well as the shallow binding site during docking. The MD simula-tion was run for deep as well as shallow site complex of NSP1 with Glycyrrhizic acid. Glycyrrhizic acid bound at the shallow site interacts mainly with Arg32, Lys36, Arg113 and Asn115 in the docked pose (figure [5](#page14)a).

The MD simulation of 20 ns suggested that the complex is stable as per RMSD plot (supplementary figure 24a). NSP1-rmsf plot indicates that the few residues of a helix along with residues at the N and

Computational search for potential COVID-19 drugs Page 13 of 18 100




Figure 3. Docking and MD simulation results for NSP1-deep-Esculin. (a) Esculin-NSP1 interactions after XP docking. (b) Interaction types and Interacting residues of NSP1 with Esculin over simulation time. Normalized stacked bars indicate the fraction of simulation time for which a particular type of interaction was maintained. Values more than 1.0 suggest that the residue forms multiple interactions of the same subtype with ligand (Esculin).




Figure 4. Docking and MD simulation results for NSP1-deep-SN00003849. (a) SN00003849-NSP1 interactions after XP docking. (b) Interaction types and Interacting residues of NSP1 with SN00003849 over simulation time. Normalized stacked bars indicate the fraction of simulation time for which a particular type of interaction was maintained. Values more than 1.0 suggest that the residue forms multiple interactions of the same subtype with ligand (SN00003849).

C-termini are also involved in an interaction with Glycyrrhizic acid (supplementary figure 24b). Major interacting residues of NSP1 are the same as those in the docking pose (figure [5](#page14)b). Atom wise interactions of Glycyrrhizic acid with NSP1 has been shown in fig-ure 24c. Similar to SN00003849, Glycyrrhizic acid also maintains at least 4 contacts with NSP1 over the entire course of simulation time (figure 24d). Gly-cyrrhizic acid bound at the deep site is not stable (-supplementary figure 23). Interestingly, Glycyrrhizic acid is from the plant Mulethi or Liquorice (also referred to as Yashtimadhura (Glycyrrhiza glabra), which is a natural herb for cough and has expectorant properties. It can also reduce infection of the upper

respiratory tract. It may reduce throat irritation and helps cases of a chronic cough.

The ADME related properties for compounds like Gingerenone, Shogaol and SN00103215 follow Lip-inski’s rule of five, while others violate either one or 3 of the 4 rules of Lipinski’s rule of five (supplementary table 1). Qikprop also summarizes the drug-likeness of compounds by comparing the properties of query compounds with known drugs. Gingerenone, Shogaol and SN00103215 are observed to not retain any star (please see Methods) suggesting strong drug-likeliness of these compounds. The water solubility, a key parameter required for absorption and distribution of the compounds, ranges from - 5.101 to 0.261 and it

100 Page 14 of 18 A Sharma, V Tiwari and R Sowdhamini




Figure 5. Docking and MD simulation results for NSP1-shallow-Glycyrrhizic acid. (a) Glycyrrhizic acid-NSP1 interactions after XP docking. (b) Interaction types and Interacting residues of NSP1 with Glycyrrhizic acid over simulation time. Normalized stacked bars indicate the fraction of simulation time for which a particular type of interaction was maintained. Values more than 1.0 suggest that the residue forms multiple interactions of the same subtype with ligand (Glycyrrhizic acid).

falls within the acceptable range. Cell permeability is important for metabolism and it was found that most of the compounds have poorly predicted cell permeability. However, the cell permeability predictions are for non-active transport. Gingerenone and Shogaol also show a high percentage of oral absorption (supplementary table 1).

4. Discussion

COVID-19 outbreak has turned into a pandemic, which makes the identification of new target molecules, repurposing of drugs and designing vaccine an immi-nent necessity. Since the outbreak, many studies have been conducted along these lines (Chakraborti et al. [2020](#page16); Gordon et al. [2020](#page16); Narayanan and Nair [2020](#page17); Wu et al. [2020a](#page17)) (Manfredonia et al. [2020](#page16); Quimque et al. [2020](#page17)). We used NSP1 protein as our target pro-tein. It shows 86 % identity with SARS NSP1. A model of COVID-19 NSP1 was made using SARS NSP1 as a template. Please note: During the submission process for this manuscript, the structure of NSP1 with the ribosome has been solved by another group (Thoms et al. [2020](#page17)). This is not published yet, nor any mention of PDB id submissions. This preprint showed the role of NSP1 in translational shutdown and innate immune evasion). Understanding the genetic diversity of a viral gene is key in understanding evolutionary pressure and add one more dimension to virtual screening (Kasib-hatla et al. [2020](#page16); Somasundaram et al. [2020](#page17)). NSP1 is evolving with key residues being conserved. Virtual screening, against NSP1 protein, suggests a list of FDA-approved drugs and natural compounds against

the deep and shallow binding site on NSP1. Deep and shallow binding sites include functionally important residues such as H81, H83, R124 and R43, K47, E91, R124, K125 respectively (AR Jauregui et al. [2013](#page16)). R124 has shown to be important for NSP1 to interact with viral mRNA 50 -UTR region which prevents viral mRNA from NSP1 mediated mRNA degradation (Kamitani et al. [2006](#page16)) (Note: Residue number in modelled structure starts with 12th residue of the sequence). Docking and MMGBSA scores suggest the binding potential of these compounds towards NSP1. Further, MD simulation of the selected compounds in complex with NSP1 ensures that some of these hits form stable interactions with NSP1.

Esculin, Cidofovir, Edoxudine, Brivudine and Remdesivir were found to form a stable complex with NSP1, among FDA-approved drugs binding at deep site of NSP1. Esculin is a glucoside and naturally occurs in barley, horse chestnut, etc. It is given to improve capillary permeability and fragility and has been reported to inhibit collagenase and hyaluronidase enzymes. This molecule has been shown to have antioxidant and anti-inflammatory activity (Wishart et al. [2018](#page17)). This suggests the ability of esculin to not only inhibit NSP1 activity but also being effective against secondary symptoms such as inflammation. Cidofovir is a known anti-viral agent against CMV infection and acts via inhibition of CMV DNA Poly-merase. Edoxudine is a deoxy-thymidine analog shown to be effective against herpes simplex virus type 1 and type 2. It acts as a competitive inhibitor of viral DNA polymerase in its phosphorylated form. Edoxudine is initially phosphorylated by viral thymidine kinas and it is specifically incorporated in viral DNA. Edoxudine

Computational search for potential COVID-19 drugs Page 15 of 18 100

has been discontinued. Brivudine is an organic com-pound and a pyrimidine 20 -deoxyribonucleosides ana-log. This is used in the treatment of herpes zoster, results from reactivation of varicella-zoster virus. Remdesivir is proposed as a potential antiviral drug against Ebola (Wishart et al. [2018](#page17)). However, this molecule appears within the Investigational group of DRUGBANK. It is an adenosine-triphosphate analog and has shown effectivity against coronaviruses. A recent publication on COVD-19 treatment, shows it to be a potential drug along with chloroquinone (Wang et al. [2020](#page17)). Remdesivir is an RNA polymerase inhi-bitor. Hence our study suggests an additional mecha-nism of action for this drug. An interesting and unexpected molecule among this list is lactose. Lactose is a disaccharide of glucose and galactose and used as nutrient supplement. Derivatives of lactose, 30 -sialyl-lactose have been shown to have broad-spectrum neutralization activity against avian influenza viruses in chickens (Pandey et al. [2018](#page17)). Further investigation is necessary to check the anti-viral property of lactose against coronavirus.

Acarbose, Iopromide and Glycyrrhizic Acid form stable interactions with the shallow binding site of NSP1. Acarbose is an alpha-glucosidase inhibitor and administered to patients with non-insulin-dependent diabetes mellitus (Wishart et al. [2018](#page17)). As the death rate among COVD-19 patients with diabetes is high, the anti-diabetic nature of acarbose can be highly useful in the treatment regime. Iopromide is a contrast agent, used in radiographic studies. Glycyrrhizic acid is a plant product obtained form Mulethi or Liquorice (also referred as Yashtimadhura (Glycyrrhiza glabra)). It has been shown to have anti-inflammatory, anti-di-abetic, anti-oxidant, anti-tumor and anti-viral properties (Ming and Yin [2013](#page17)). These properties suggest Gly-cyrrhizic acid to be of high importance in COVID-19 treatment.

We next pursued virtual screening against supernat-uraldb – a database of 3,25,287 natural small molecules (giving rise to 5,03,604 confirmations). Virtual screening for the shallow site also predicted natural products with high medicinal value such as Gin-gerenone A (SN00156190) and Shogaol (SN00002189), but with lower docking score (table [1](#page7)). Gingerenone A has anti-obesity, anti-inflammatory and antibiotic properties (Rampogu et al. [2018](#page17); Suk et al. [2017](#page17)), whereas Shogaol is anticancer, anti-oxidant, antimicrobial, anti-inflammatory anti-allergic and antibiotic in nature (Rampogu et al. [2018](#page17); Semwal et al. [2015](#page17)). MD simulation was not performed for the above two because of their lower rank but can be tested

further. Molecules like Galangin, Gingerenone and Shaogaol are reported in high quantities in the medic-inal plant, Sitharathai (Alpinia Officinarum; a form of ginger, also referred as ‘Kulanjan’ (Chen et al. [2019](#page16)) which has been used for bronchial infections, as a carminative and recently recognized for its antiviral properties (Pillai and Young [2017](#page17)). Extracts from herbal plants provide a host of secondary metabolites which could have a combinatorial effect to reduce the viral load, once consumed in the proper manner.

Other hits from supernaturaldb include compounds SN00003849, SN00003832 and SN00216190, which were found to have stable interactions with the deep binding site of NSP1 as suggested by docking and MD simulation. Therefore, along with FDA-approved drugs which will constitute the treatment by repurposing, these new natural compounds can also be tested for their activity against COVID-19.

5. Conclusion

Virtual screening helps in the identification of novel drug candidates and repurposing of known drugs. The current pandemic caused by SARS-Cov2. In order to assist in the development of a cure, we have targeted NSP1 protein of this virus and screened known drugs and natural com-pounds against it. In this effort, we have identified known antiviral compounds like Remdesivir and Edoxudine. Other drugs, like Esculin and Acarbose which are not antiviral, but are used as anti-inflammatory and antidia-betic (respectively) were also identified. These FDA-ap-proved drugs can be considered as potential candidates for drug repurposing. Natural compounds like Gly-cyrrhizic acid (entry 19 in table [1](#page7)) from Liquorice and Galangan, Gingeronone and Shogaol (entries 18, 32 and 33 in table [1](#page7)) from Sitharathai, were also found to be interacting with NSP1. These compounds can be con-sidered as novel drug candidates against COVID-19. We find these results to be encouraging and hopefully useful immediately to the community and follow-up validation by other researchers.

Acknowledgements

We would like to thank NCBS (TIFR) for infrastruc-tural facilities. The authors thank Dr. Radhika Venkatesan for useful discussions. RS would like to acknowledge her JC Bose fellowship (JC Bose fel-lowship (SB/S2/JC-071/2015)) from the Science and Engineering Research Board, India.

100 Page 16 of 18 A Sharma, V Tiwari and R Sowdhamini

References

Banerjee P, Erehman J, Gohlke B-O, Wilhelm T, Preissner R, et al. 2015 Super Natural II—a database of natural products. Nucleic Acids Res. 43 D935–D939

Berman H, Henrick K and Nakamura H 2003 Announcing the worldwide Protein Data Bank. Nat. Struct. Mol. Biol. 10 980. <https://doi.org/10.1038/nsb1203-980>

Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, et al. 2006 Scalable algorithms for molecular dynamics simu-lations on commodity clusters. SC ‘06: Proceedings of the 2006 ACM/IEEE conference on Supercomputing [https://](https://doi.org/10.1145/1188455.1188544) [doi.org/10.1145/1188455.1188544](https://doi.org/10.1145/1188455.1188544)

Brister JR, Ako-Adjei D, Bao Y and Blinkova O 2015 NCBI viral Genomes resource. Nucleic Acids Res. 43 D571–D577 Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, et al. 2009 BLAST?: Architecture and applications.

BMC Bioinform. 10 421

Channappanavar R and Perlman S 2017 Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immuno-pathol. 39 529–539

Chakraborti S, Bheemireddy S and Srinivasan N 2020 Repurposing drugs against main protease of SARS-CoV-

1. mechanism based insights supported by available laboratory and clinical data. [https://doi.org/10.26434/](https://doi.org/10.26434/chemrxiv.12057846.v2) [chemrxiv.12057846.v2](https://doi.org/10.26434/chemrxiv.12057846.v2)

Chen CY, Lin CL, Kao CL, Yeh HC, Li HT et al. 2019 Secondary Metabolites from the Rhizomes of Alpinia officinarum. Chem. Nat. Compounds 55 1176–1178

Deftereos S, Giannopoulos G, Vrachatis DA, Siasos G, Giotaki SG et al. 2020 Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks? Eur Heart J Cardiovasc. Pharma-cother. <https://doi.org/10.1093/ehjcvp/pvaa033>

Elbe S and Buckland-Merrett G 2017 Data, disease and diplomacy: GISAID’s innovative contribution to global health. Global Challenges 1 33–46

Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D et al. 2006 Comparative protein structure modeling using modeller. Curr. Protocols Bioinform. <https://doi.org/10.1002/0471250953.bi0506s15>

Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ et al. 2004 Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47 1739–1749

Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR et al. 2006 Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49 6177–6196

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K et al. 2020 A SARS-CoV-2-Human protein-protein inter-action map reveals drug targets and potential drug-repurposing. bioRxiv [https://doi.org/10.1101/2020.03.22.](https://doi.org/10.1101/2020.03.22.002386) [002386](https://doi.org/10.1101/2020.03.22.002386)

Halgren T 2007 New method for fast and accurate binding-site identification and analysis. Chem. Biol. Drug Design

1. 146–148

Halgren TA 2009 Identifying and characterizing binding sites and assessing druggability. J. Chem. Inform. Model.

1. 377–389

Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL et al. 2004 Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47 1750–1759

Harder E, Damm W, Maple J, Wu C, Reboul M et al. 2016 OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. J. Chem. Theory Comput. 12 281–296

Hatcher EL, Zhdanov SA, Bao Y, Blinkova O, Nawrocki EP et al. 2017 Virus Variation Resource-improved response to emergent viral outbreaks. Nucleic Acids Res. 45 D482–D490 Huang C, Lokugamage KG, Rozovics JM, Narayanan K, Semler BL et al. 2011 SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: Viral mRNAs are resistant to nsp1-induced

RNA cleavage. PLoS Pathogens 7 e1002433 Humphreys DD, Friesner RA and Berne BJ 1994 A

multiple-time-step molecular dynamics algorithm for macromolecules. J. Phys. Chem. 98 6885–6892

Jauregui AR, Savalia D, Lowry VK, Farrell CM and Wathelet MG 2013 Identification of residues of SARS-CoV nsp1 that differentially affect inhibition of gene expression and antiviral signaling. PLoS ONE 8 1–11

Kamitani W, Huang C, Narayanan K, Lokugamage KG and Makino S 2009 A two-pronged strategy to suppress host protein synthesis by SARS coronavirus NSP1 protein. Nat. Struct. Mol. Biol. 16 1134–1140

Kamitani W, Narayanan K, Huang C, Lokugamage K, Ikegami T et al. 2006 Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc. Nat. Acad.Sci. USA 103 12885–12890

Kasibhatla SM, Kinikar M, Limaye S, Kale MM and Kulkarni-Kale U 2020 Understanding evolution of SARS-CoV-2: A perspective from analysis of genetic diversity of RdRp gene. J. Med. Virol. https://doi.org/10.1002/ jmv.25909

Laskowski RA, MacArthur MW, Moss DS and Thornton JM 1993 PROCHECK: a program to check the stereochem-ical quality of protein structures. J. Appl. Crystallogr. 26 283–291

Law AHY, Lee DCW, Cheung BKW, Yim HCH and Lau ASY 2007 Role for nonstructural protein 1 of severe acute respiratory syndrome coronavirus in chemokine dysreg-ulation. J. Virol. 81 416–422

Manfredonia I, Nithin C, Ponce-Salvatierra A, Ghosh P, Wirecki TK et al. 2020 Genome-wide mapping of therapeutically-relevant SARS-CoV-2 RNA structures. bioRxiv <https://doi.org/10.1101/2020.06.15.151647>

Computational search for potential COVID-19 drugs Page 17 of 18 100

Martyna GJ, Klein ML and Tuckerman M 1992 Nos \’ e - Hoover chains: The canonical ensemble via continuous dynamics. J. Chem. Phys.

Martyna GJ, Tobias DJ and Klein ML 1994 Constant pressure molecular dynamics algorithms. J. Chem. Phys.

1. https://doi.org/10.1063/1.467468

Masters PS 2006 The molecular biology of coronaviruses. Adv. Virus Res. 65 193–292

Ming LJ and Yin ACY 2013 Therapeutic effects of glycyrrhizic acid. Nat. Prod. Commun. 8(3) 415–418 Narayanan K, Huang C, Lokugamage K, Kamitani W,

Ikegami T et al. 2008 Severe Acute Respiratory Syn-drome Coronavirus nsp1 suppresses host gene expression, including that of type i interferon, in infected cells. J. Viro. 82 4471–4479

Narayanan K, Ramirez SI, Lokugamage KG and Makino S 2015 Coronavirus nonstructural protein 1: Common and distinct functions in the regulation of host and viral gene expression. Virus Res. 202 89–100

Narayanan N and Nair DT 2020 Vitamin B12 may inhibit RNA-dependent-RNA polymerase activity of nsp12 from the SARS-CoV-2 virus. Preprints [https://doi.org/10.](https://doi.org/10.20944/preprints202003.0347.v1) [20944/preprints202003.0347.v1](https://doi.org/10.20944/preprints202003.0347.v1)

Pandey RP, Kim DH, Woo J, Song J, Jang SH et al. 2018 Broad-spectrum neutralization of avian influenza viruses by sialylated human milk oligosaccharides: In vivo assessment of 30 -sialyllactose against H9N2 in chickens. Sci. Rep. 8 2563

Pfefferle S, Schpf J, Kgl M, Friedel CC, Mller MA et al. 2011 The SARS-Coronavirus-host interactome: Identifi-cation of cyclophilins as target for pan-Coronavirus inhibitors. PLoS Pathogens 7 [https://doi.org/10.1371/](https://doi.org/10.1371/journal.ppat.1002331) [journal.ppat.1002331](https://doi.org/10.1371/journal.ppat.1002331)

Pickett BE, Sadat EL, Zhang Y, Noronha JM, Squires RB et al. 2012 ViPR: An open bioinformatics database and analysis resource for virology research. Nucleic Acids Res. 40 D593–D598

Pillai MK and Young DJ 2017 Therapeutic potential of Alpinia officinarum. Mini Rev. Med. Chem. 18 1220–1232

Piplani S, Singh PK, Winkler DA and Petrovsky N 2020 In silico comparison of spike protein-ACE2 bind-ing affinities across species; significance for the possible origin of the SARS-CoV-2 virus. [arXiv:](http://arXiv.org/abs/2005.06199) [2005.06199](http://arXiv.org/abs/2005.06199)

Quimque MTJ, Notarte KIR, Fernandez RAT, Mendoza MAO, Liman RAD et al. 2020 Virtual screening-driven drug discovery of SARS-COV2 enzyme inhibitors tar-geting viral attachment, replication, post-translational modification and host immunity evasion infection mech-anisms. J. Biomol. Struct. Dyn. 10.1080/ 07391102.2020.1776639

Rampogu S, Baek A, Gajula RG, Zeb A, Bavi RS et al. 2018

Ginger (Zingiber officinale) phytochemicals-gingerenone-

A and shogaol inhibit SaHPPK: Molecular docking,

molecular dynamics simulations and in vitro approaches. Ann. Clin. Microbiol. Antimicrob. 17 16

Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W 2013 Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design 27 221–234

Semwal RB, Semwal DK, Combrinck S and Viljoen AM 2015 Gingerols and shogaols: Important nutraceutical principles from ginger. Phytochemistry 117 554–568

Shannon CE 1948 A mathematical theory of communica-tion. The Bell System Technical Journal 27 379–423

Shen Z, Wang G, Yang Y, Shi J, Fang L et al. 2019 A conserved region of nonstructural protein 1 from alpha-coronaviruses inhibits host gene expression and is critical for viral virulence. Journal of Biological Chemistry 294 13606–13618

Somasundaram K, Mondal M and Lawarde A 2020 Genomics of Indian SARS-CoV-2: Implications in genetic diversity, possible origin and spread of virus. [https://doi.](https://doi.org/10.1101/2020.04.25.20079475) [org/10.1101/2020.04.25.20079475](https://doi.org/10.1101/2020.04.25.20079475)

Suk S, Kwon GT, Lee E, Jang WJ, Yang H et al. 2017 Gingerenone A, a polyphenol present in ginger, sup-presses obesity and adipose tissue inflammation in high-fat diet-fed mice. Mol. Nutr. Food Res. 61 [https://doi.org/](https://doi.org/10.1002/mnfr.201700139) [10.1002/mnfr.201700139](https://doi.org/10.1002/mnfr.201700139)

Tanaka T, Kamitani W, DeDiego ML, Enjuanes L and Matsuura Y 2012 Severe Acute Respiratory Syndrome Coronavirus nsp1 facilitates efficient propagation in cells through a specific translational shutoff of host mRNA. J. Virol. 86 11128–11137

Thoms M, Buschauer R, Ameismeier M, Koepke L, Denk T et al. 2020 Structural basis for translational shutdown and immune evasion by the NSP1 protein of SARS-CoV-2. bioRxiv [https://doi.org/10.1101/2020.05.18.](https://doi.org/10.1101/2020.05.18.102467) [102467](https://doi.org/10.1101/2020.05.18.102467)

Wang M, Cao R, Zhang L, Yang X, Liu J et al. 2020 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30 269–271

Wiederstein M and Sippl MJ 2007 ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res.

1. W407–W410

Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A et al. 2018 DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46 D1074– D1082

Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS et al. 2004 Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol.

1. 95–103

Wu C, Liu Y, Yang Y, Zhang P, Zhong W et al. 2020a Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.

100 Page 18 of 18 A Sharma, V Tiwari and R Sowdhamini

Acta Pharmaceut. Sinica B [https://doi.org/10.1016/j.apsb.](https://doi.org/10.1016/j.apsb.2020.02.008) [2020.02.008](https://doi.org/10.1016/j.apsb.2020.02.008)

Wu F, Zhao S, Yu B, Chen Y-M, Wang W, et al. 2020b A new coronavirus associated with human respiratory disease in China. Nature 579 265–269

Zst R, Cervantes-Barragn L, Kuri T, Blakqori G, Weber F, et al. 2007 Coronavirus non-structural protein 1 is a major pathogenicity factor: Implications for the rational design of coronavirus vaccines. PLoS Patho-gens 3 e109

Corresponding editor: SREENIVAS CHAVALI